Guillemette E Benoist
Overview
Explore the profile of Guillemette E Benoist including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hulskotte L, Wilbrink-Pijffers I, Arbouw M, Benoist G, Jansman F, van Berlo-van de Laar I
Biomed Chromatogr
. 2024 Apr;
38(7):e5874.
PMID: 38587098
A sensitive and reliable LC-MS/MS method was developed and validated for the quantification of oxycodone and metabolites in human plasma. The method has a runtime of 6 min and a...
2.
Boerrigter E, Overbeek J, Benoist G, Somford D, Hamberg P, Tol J, et al.
Eur Urol Oncol
. 2024 Mar;
7(6):1376-1383.
PMID: 38485614
Background And Objective: Enzalutamide is a potent androgen receptor signalling inhibitor, effectively used for the treatment of different stages of prostate cancer. Side effects occur frequently at the registered dose,...
3.
Tolmeijer S, Boerrigter E, Sumiyoshi T, Kwan E, Ng S, Annala M, et al.
Clin Cancer Res
. 2023 Mar;
29(15):2835-2844.
PMID: 36996325
Purpose: Androgen receptor pathway inhibitors (ARPI) are standard of care for treatment-naïve metastatic castration-resistant prostate cancer (mCRPC), but rapid resistance is common. Early identification of resistance will improve management strategies....
4.
Boerrigter E, Benoist G, van Oort I, Verhaegh G, de Haan A, van Hooij O, et al.
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944897
Treatment evaluation in metastatic castration-resistant prostate cancer is challenging. There is an urgent need for biomarkers to discriminate short-term survivors from long-term survivors, shortly after treatment initiation. Thereto, the added...
5.
Boerrigter E, Benoist G, Overbeek J, Donders R, Mehra N, van Oort I, et al.
Br J Clin Pharmacol
. 2021 Aug;
88(3):1170-1178.
PMID: 34436788
Aims: To assess whether the exposure-response relation for abiraterone is different in pre-chemotherapy patients compared to post-chemotherapy patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: Data were collected from three...
6.
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance
Cantet G, Berges A, OSullivan R, Cohen-Rabbie S, Dota C, Dubois V, et al.
Br J Clin Pharmacol
. 2021 Aug;
88(3):1010-1019.
PMID: 34416045
Aims: Concentration-QT modelling (C-QTc) of first-in-human data has been rapidly adopted as the primary evaluation of QTc interval prolongation risk. Here, we evaluate the performance of C-QTc in early oncology...
7.
Boerrigter E, Benoist G, van Oort I, Verhaegh G, van Hooij O, Groen L, et al.
Mol Oncol
. 2021 Mar;
15(9):2453-2465.
PMID: 33650292
Circulating RNAs extracted from liquid biopsies represent a promising source of cancer- and therapy-related biomarkers. We screened whole blood from patients with metastatic castration-resistant prostate cancer (mCRPC) following their first-line...
8.
Benoist G, van Oort I, Boerrigter E, Verhaegh G, van Hooij O, Groen L, et al.
Clin Chem
. 2020 May;
66(6):842-851.
PMID: 32408351
Background: Several treatment options were recently added for metastatic castration-resistant prostate cancer (mCRPC). However, response to therapy is variable, and biomarkers that can guide treatment selection and response evaluation are...
9.
Benoist G, van Oort I, Burger D, Mehra N, van Erp N
Cancer Chemother Pharmacol
. 2020 Feb;
85(4):753-760.
PMID: 32076807
Purpose: The aim of the study is to investigate the influence of patient characteristics, age and body mass index (BMI), on pharmacokinetics of enzalutamide, and to study the relationships between...
10.
Lubberman F, Benoist G, Gerritsen W, Burger D, Mehra N, Hamberg P, et al.
Cancer Chemother Pharmacol
. 2019 Sep;
84(6):1179-1185.
PMID: 31515667
Purpose: Abiraterone acetate is used at a fixed oral dose of 1000 mg once daily (OD) taken fasted. By administering abiraterone acetate with food, a reduced dose can potentially be...